T
Tami L. Mark
Researcher at RTI International
Publications - 117
Citations - 3519
Tami L. Mark is an academic researcher from RTI International. The author has contributed to research in topics: Medicaid & Mental health. The author has an hindex of 35, co-authored 107 publications receiving 3170 citations. Previous affiliations of Tami L. Mark include Thomson Reuters & Brandeis University.
Papers
More filters
Journal ArticleDOI
The economic costs of heroin addiction in the United States.
TL;DR: The large economic burden resulting from heroin addiction highlights the importance of investment in prevention and treatment, both to the addict and society at large.
Journal ArticleDOI
Alcohol and opioid dependence medications: Prescription trends, overall and by physician specialty
TL;DR: While acamprosate and buprenorphine grew rapidly after market entry, overall substance abuse retail medication sales remain small relative to the size of the population that could benefit from treatment and relative to sales for other medications, such as antidepressants.
Journal Article
Impact of statin copayments on adherence and medical care utilization and expenditures.
Teresa B. Gibson,Tami L. Mark,Kirsten Axelsen,Onur Baser,Dale A. Rublee,Kimberly A. McGuigan +5 more
TL;DR: Lower statin copayments were associated with higher levels of statin adherence and policy makers and plan managers should consider interventions that improve adherence to statins, such as lowerCopayments.
Journal ArticleDOI
Changes In US Spending On Mental Health And Substance Abuse Treatment, 1986–2005, And Implications For Policy
TL;DR: The recent recession, the full implementation of federal parity law, and such health reform-related actions as the planned expansion of Medicaid all have the potential to improve access to mental health and substance abuse treatment and to alter spending patterns further.
Journal ArticleDOI
Understanding US addiction physicians' low rate of naltrexone prescription.
TL;DR: Multivariate results indicated that physician perceptions of naltrexone's effectiveness and safety were significantly associated with prescribing, and physicians who had more exposure to information about the product were more likely to prescribe it.